Chembio Diagnostics Inc. [CEMI] shares are up more than 14.84% this year and recently increased 0.07% or $0.35 to settle at $4.91. Analysts expect CEMI to grow earnings at a 25.00% annual rate over the next 5 years. CEMI has a short ratio of 2.25. This implies that the market is currently less bullish on the outlook for CEMI.

On 13, November 2020, Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil. According to news published on Yahoo Finance, Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received regulatory approval from Agência Nacional de Vigilância Sanitária (ANVISA) to market the DPP SARS-CoV-2 Antigen test system in Brazil.

Analyst Birdseye View:

The most recent analyst activity for Chembio Diagnostics Inc. [NASDAQ:CEMI] stock was on June 17, 2020, when it was Downgrade with a Hold rating from The Benchmark Company. Before that, on November 06, 2020, Colliers Securities Recapitulated a Buy rating and elevated its amount target to $7.50. On June 17, 2020, Craig Hallum Downgrade a Hold rating. On June 17, 2020, Canaccord Genuity Downgrade a Hold rating and increased its price target to $7. On May 26, 2020, Robert W. Baird Initiated an Outperform rating and increased its price target to $21. On March 04, 2020, The Benchmark Company Reiterated a Speculative buy rating and boosted its amount target on this stock to $6. On March 04, 2020, The Benchmark Company Reiterated a Speculative buy rating and decreased its target amount on this stock from $9 to $5.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.25 and a peak of $15.89. Right now, the middling Wall Street analyst 12-month amount mark is $6.25. At the most recent market close, shares of Chembio Diagnostics Inc. [NASDAQ:CEMI] were valued at $4.91. According to the average price forecast, investors can expect a potential return of 0.0%.

FUNDAMENTAL ANALYSIS

Chembio Diagnostics Inc. [NASDAQ:CEMI] most recently reported quarterly sales of 10.27 billion, which represented growth of 6.20%. This publicly-traded organization’s revenue is $106,370 per employee, while its income is -$42,207 per employee. This company’s Gross Margin is currently 25.10%, its Operating Margin is -68.10%, its Pretax Margin is -41.13, and its Net Margin is -39.68. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -24.65, -47.68, -30.26 and -33.22 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 51.55 and the whole liability to whole assets at 36.51. It shows enduring liability to the whole principal at 49.96 and enduring liability to assets at 0.35 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 4.67 points at 1st support level, the second support level is making up to 4.42. But as of 1st resistance point, this stock is sitting at 5.09 and at 5.26 for 2nd resistance point.

Chembio Diagnostics Inc. [CEMI] reported its earnings at -$0.28 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.26/share signifying the difference of -0.02 and -7.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.42 calling estimates for -$0.39/share with the difference of -0.03 depicting the surprise of -7.70%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Chembio Diagnostics Inc. [NASDAQ:CEMI] is 4.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.84. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.24 and it’s amount to book ratio is 3.36.